CytomX Therapeutics filings document a Delaware clinical-stage oncology biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under CTMX. Recent 8-K reports furnish quarterly and annual financial results, business updates, clinical-program disclosures for Varseta-M and other PROBODY programs, and clinical safety reporting tied to the company’s development studies.
Its formal records also cover capital structure and financing activity, including a completed public offering of common stock and pre-funded warrants made through a Form S-3 registration framework. Proxy materials describe board elections, auditor ratification, authorized-share amendments, equity incentive plan matters, executive compensation, and stockholder voting procedures.
CytomX Therapeutics director Alan Ashworth received a grant of stock options covering 59,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 16, 2036.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or the 2027 annual meeting of stockholders, assuming he continues to serve as a director through that date. Following this grant, he holds options for 59,000 shares directly.
CytomX Therapeutics, Inc. reported that director Elaine V. Jones received a stock option grant. She was awarded options to acquire 59,000 shares of common stock at an exercise price of $2.96 per share, giving her rights to buy shares at that price in the future.
After this grant, she holds 59,000 derivative securities linked to common stock. According to the terms, all 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 annual stockholder meeting, assuming she continues serving as a director until that vesting date.
CytomX Therapeutics Chief Financial Officer Christopher Ogden reported an open-market sale of 1,624 shares of common stock on June 15, 2026 at an average price of $3.05 per share. According to the disclosure, the shares were sold solely to satisfy tax and other government withholding obligations arising from the vesting of restricted stock units, so the transaction reflects a tax-related event rather than a discretionary portfolio move.
After this sale, Ogden holds a total of 295,324 shares of CytomX Therapeutics common stock, including 167,249 restricted stock units that will convert into shares as they vest over time. The sale represents a small portion of his overall direct equity position, indicating that he retains substantial exposure to the company’s stock following this routine tax-withholding transaction.
CytomX Therapeutics updated its cancer drug collaboration with Regeneron through Amendment No. 4 to their 2022 Collaboration and License Agreement. The amendment, effective May 31, 2026, extends the period in which Regeneron can select additional drug programs and allows for up to eight more collaboration programs.
Regeneron has already nominated the first two of these additional programs, which entitle CytomX to receive $37.0 million in aggregate target nomination payments. Across all potential programs, the Agreement provides for up to approximately $4 billion in target nomination, preclinical, clinical, regulatory and commercial milestone payments, while previously disclosed tiered royalty terms remain unchanged.
CytomX Therapeutics ownership disclosure: Seven Fleet Master Fund and related reporting persons report beneficial ownership of 1,085,398 shares of Common Stock, representing 0.5% of the class.
The filing states the 217,702,919 shares outstanding as of April 30, 2026 were reported in the issuer's Form 10-Q filed May 7, 2026. The statement also notes that Longitude may be deemed to beneficially own 15,288,461 shares (7.0%) based on information provided to the reporting persons; the reporting persons disclaim group membership.
CytomX Therapeutics ownership update from Longitude-related entities and principals. The joint filing reports that Longitude Capital Partners V, LLC and Longitude Venture Partners V, L.P. each have shared beneficial ownership of 12,458,461 shares (each 5.7% of the class), and that Longitude 103.8 East entities hold 2,830,000 shares (1.3%). Reporting individuals Patrick G. Enright and Juliet Tammenoms Bakker are each reported with shared beneficial ownership of 15,288,461 shares (7.0% each). The filing cites 217,702,919 shares outstanding as of April 30, 2026 as reported in the issuer’s Form 10-Q.
CytomX Therapeutics — Amendment No. 2 to a Schedule 13G/A reports that a group of Venrock-related entities and two individuals beneficially owned 9,982,124 shares of CytomX common stock as of March 31, 2026.
The filing states the group’s position consists of 2,107,644 shares held by Venrock Healthcare Capital Partners III, 210,912 shares held by VHCP Co-Investment Holdings III, and 7,663,568 shares held by Venrock Healthcare Capital Partners EG. The percentage figures are calculated using 170,186,742 shares outstanding as of February 28, 2026 plus 45,990,567 shares issued in a public offering that closed on March 19, 2026, producing the reported 4.6% ownership figure shown on the cover pages.
CytomX Therapeutics: Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang filed an Amendment No. 1 to a Schedule 13G/A reporting 15,013,093 shares of Common Stock, representing 6.90% of the class.
The filing lists shared voting and dispositive power over the reported 15,013,093 shares. Signatures show the filing was executed on 05/15/2026.
CytomX Therapeutics reports that Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund each beneficially own 10,098,824 shares of common stock, representing 4.6% of the class. The filing states there were 217,702,919 outstanding shares as of April 30, 2026.
The report attributes the holdings to the Master Fund (direct holder) and notes that Perceptive Advisors serves as investment manager and Mr. Edelman is managing member; all three disclose shared voting and dispositive power over the 10,098,824 shares.
CytomX Therapeutics reported Q1 2026 revenue of $10.3 million and a net loss of $18.2 million, compared with $50.9 million of revenue and $23.5 million of net income a year earlier. The drop in revenue primarily reflects completion of collaboration performance obligations in 2025.
Cash, cash equivalents and investments rose to $346.7 million as of March 31, 2026, helped by a $250 million equity follow-on offering, giving an expected cash runway to at least the second half of 2028. The company highlighted positive Phase 1 data and completed 40‑patient dose optimization enrollment for its EpCAM ADC Varseta‑M in advanced colorectal cancer, and ongoing development of CX‑801, including a KEYTRUDA® combination study in melanoma.